CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01849055
NCT01849055Phase 1Completed
CompareCT.gov

A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects

Eli Lilly and Company·interventional·Posted May 8, 2013·Updated Dec 14, 2018

In Brief

A Phase 1 clinical trial evaluating Placebo, LY3023703, and 1 other intervention for Healthy Volunteers. Completed, enrolled 48 participants across 1 site.

Detailed Summary

This is a study of LY3023703 in healthy participants. The purposes of this study are to look at safety, how well the study drug is tolerated, how much of the study drug gets into the blood stream and how long it takes the body to remove the study drug. The effects of LY3023703 on blood pressure after 28 days of dosing will be studied. Information about any side effects that occur will be collected. The study is expected to last 21 weeks.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 8, 2013
Enrollment StartMay 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 13.2 years ago

Interventions

Placebodrug

Administered orally

LY3023703drug

Administered orally

Celecoxibdrug

Administered orally